New AI Blood Test Predicts Heart Disease 15 Years Early
Date: July 19, 2026
Source: The University of Hong Kong
Summary: A groundbreaking AI-powered blood test could give people a remarkably early warning of serious heart and circulation problems. Developed by researchers at the University of Hong Kong, CardiOmicScore analyzes thousands of proteins and metabolites to estimate the risk of six major cardiovascular diseases (CVDs), including heart attack, stroke, heart failure, and atrial fibrillation. Unlike genetic risk scores, which remain fixed throughout life, this system captures biological changes linked to a person's current health, lifestyle, and environment.
Full Story
Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have developed an artificial intelligence tool that may help predict serious cardiovascular problems many years before symptoms appear. This innovation, announced in July 2026, leverages cutting-edge proteomics and metabolomics to offer a dynamic risk assessment that adapts to an individual's evolving health status.
The system, known as CardiOmicScore, uses information from a single blood test to estimate a person's future risk of six major cardiovascular diseases: coronary artery disease, stroke, heart failure, atrial fibrillation, peripheral artery disease, and venous thromboembolism. In people at elevated risk, the model detected warning signals as far as 15 years before clinical onset, potentially revolutionizing preventive cardiology.
The findings were published in Nature Communications.
A Blood Test That Captures Current Health
Cardiovascular diseases remain the leading cause of death worldwide, accounting for approximately 19.8 million fatalities in 2022 alone. Traditional risk assessment—based on factors like age, blood pressure, smoking history, and cholesterol levels—has been a cornerstone of preventive medicine. However, these standard clinical measurements may not reveal the earliest biological changes occurring inside the body before a disease becomes apparent.
As a result, some individuals may not be identified as high risk until the optimal window for prevention has already begun to close. In 2026, with rising global rates of metabolic syndrome and sedentary lifestyles, the need for earlier detection is more pressing than ever.
Beyond Genetic Risk Scores
Genetic risk tests, such as polygenic risk scores (PRS), offer another way to estimate a person's likelihood of developing disease by combining the effects of many genetic variants into a single measure of inherited risk. However, a person's genetic makeup is largely fixed at birth. This means genetic scores cannot fully reflect more immediate changes caused by diet, exercise, aging, illness, environmental exposures, or other dynamic influences on health.
CardiOmicScore was designed to overcome this limitation. By analyzing thousands of proteins (the proteome) and small molecules (the metabolome) circulating in the blood, the AI model generates a snapshot of a person's current biological state. This approach captures not only inherited predispositions but also lifestyle-driven modifications, making it a more responsive and personalized tool for early risk stratification.
How the AI Works
The AI behind CardiOmicScore was trained on extensive datasets from diverse populations, ensuring its predictions are robust across different demographics. The model integrates complex biomarker patterns that correlate with developing CVDs, identifying subtle signals invisible to conventional tests. In validation studies, the system demonstrated high accuracy in distinguishing individuals who would later develop cardiovascular events from those who would remain healthy, with predictive power extending up to 15 years prior to diagnosis.
Implications for Preventive Medicine
This breakthrough has profound implications for global health. With cardiovascular diseases projected to remain the leading cause of death through 2026 and beyond, tools like CardiOmicScore could enable early interventions—such as lifestyle changes, medications, or closer monitoring—before irreversible damage occurs. The test is particularly valuable for individuals with borderline risk factors or family histories, where standard assessments might miss hidden dangers.
As the technology moves toward clinical adoption, researchers are working on cost-effective implementation strategies to make the test accessible in routine healthcare settings. Meanwhile, the HKUMed team continues to refine CardiOmicScore, exploring its potential to predict other chronic conditions.
For more information, visit the University of Hong Kong's research portal or read the full study in Nature Communications.